AGP Executive Report
Last update: 7 hours agoBiotech: OHSU researchers received $7.5 million in federal grants to develop gene therapies for rare kidney diseases that currently have no cures. Work is still largely in animal testing, with a clinical trial targeted within four years. Drug Manufacturing: Genentech has begun a $750 million expansion of its Hillsboro facility, adding 211,000 square feet and capabilities for filling drug-device combinations. The project is expected to create about 250 manufacturing jobs, with operations planned for 2031. Infant Health Research: Oregon was selected to join a study screening infants for genetic conditions, a step toward identifying some disorders earlier. Liver Health: An OHSU-led study of nearly 200,000 people linked late-night eating with a 20% to 30% higher risk of liver disease, including fatty liver disease and cirrhosis; the findings show an association, not proof that meal timing causes the conditions.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
